Ki16425 is primarily used in research to study the role of lysophosphatidic acid (LPA) receptors in various biological processes. It acts as a selective antagonist for LPA1 and LPA3 receptors, making it a valuable tool for investigating the signaling pathways and physiological functions mediated by these receptors. Researchers utilize Ki16425 to explore its potential effects on cellular processes such as proliferation, migration, and survival, particularly in the context of cancer, fibrosis, and inflammation. Additionally, it is employed in preclinical studies to assess its therapeutic potential in conditions where LPA receptor signaling is implicated, such as pulmonary fibrosis, neuropathic pain, and cardiovascular diseases. Its application helps in understanding the molecular mechanisms underlying these diseases and in identifying potential targets for drug development.